12th Global Pharmacovigilance & clinical trials summit
|12th Global Pharmacovigilance & clinical trials summit|
12th Global Pharmacovigilance & Clinical Trials Summit
The 12th Global Pharmacovigilance & Clinical Trail Summit is scheduled on July 16-17, 2018 in Sydney, Australia. This conferences is a platform for attendees to network and participate in discussions about drug development, trials, and pharmacovigilance
This is a 2 day event with presentations by and exhibition opportunities for vendors to showcase novel technologies.
Attendees who would benefit from this conference include students, scientists, researchers, and industry. 
We take great opportunity to bring to your kind notice that we are launching Global Pharmacovigilance 2018, with valuable suggestions and feedback of Global Pharmacovigilance 2017, and we would be delighted to invite you to attend at the upcoming "12th Global Pharmacovigilance & Clinical Trials Summit" during July 09-10, 2018 Sydney, Australia with the theme "Comprehend Multiple Facets of Pharmacovigilance and Clinical Trials." Conference Highlights includes:Pre-clinical Research & Clinical TrialsAdverse Drug ReactionPharmacovigilance and Risk ManagementGood Pharmacovigilance PracticeDrug SafetyClinical Trials on Various DisordersClinical Data Management and AnalysisCase Report Forms in Clinical TrialsClinical Pharmacology and BiopharmaceuticsChallenges in Pharmacy PracticeRegulatory AffairsClinical Research and StatisticsPV for biologics and biosimilarsCurrent & Future Scenario of Pharmacovigilance Submit your abstract at : http://globalpharmacovigilance.pharmaceuticalconferences.com/abstract-submission.php For more queries, email us at email@example.comYou should enter description content for your listing.
- Start Date:
- Monday, 9 July, 2018
- End Date:
- Tuesday, 10 July, 2018 5:00pm
- Biologics versus biosimilars: Are they similar molecules? Do they share similar drug safety profile?
- The latest trends of IQ and brain size and effects of lifestyle and environmental
factors on cranial capacity
- Consideration of antimicrobial resistance in Campylobacter spp. in cynomolgus monkeys from Asian countries
- Title: Challenges for sustenance
- How to do data mining in pharmacovigilance
- Adverse drug reaction reporting by patients in 50 countries
- The effectiveness of antibiotic-loaded bone cement for preventing postoperative infection in patients undergoing total knee arthroplasty
- Preparation and tumour-suppressing effects of folic acid-targeted, temperature-sensitive magnetoliposomes in ovarian cancer
- Patient safety culture in Hamad Medical Corporation (HMC), Doha, Qatar
- Challenges in breast cancer treatment and drug safety
- From visiting a physician to expecting antibiotics: Korean perspectives and practices toward respiratory tract infections
- New developments in adverse drug reaction of ART and tertiary care
- Open access pharmacovigilance databases: Analysis of 11 databases
Who should attend
Pharmacovigilance Students, Scientists
Pharmacovigilance Researchers & Teachers
Pharmacovigilance Associations and Societies
Pharmacovigilance Training Institutes
Software Developing Companies
Medical Devices Manufacturing Companies
Data Management Companies
Also, Directors/Senior Directors/Executive Directors and Vice Presidents/Senior Vice Presidents/Executive Vice Presidents and Heads/Leaders/Partners of:
CROs and CMOs Clinical Research Sites Pharma/Biotech and Medical Device industries Hospitals, Associations University Faculties scientists who are related to clinical and medical research like:
Track 1: Drug Safety
Drug safety is associated with adverse effects of pharmacological agents including side effects, product quality, and medication error in drug usage, inefficacy, and fake drugs. Patient Safety, Drug Interaction (drug-drug and food-drug interaction) Drug Pharmacokinetic, and Adverse Drug Reaction are several terms involved with Drug Safety. Companies have to conduct audits to ensure drug safety to ensure their compliance with international standards of laws, regulations, and guidance.
This track focuses on Drug Safety Updates, Drug Safety Solutions, Training, Surveillance, Services & Software, Reporting & Monitoring.
Track 2: Adverse Drug Reactions
The aim is to minimize adverse drug reactions to improve drug safety through evaluating and reporting adverse events. PK-PD studies are also used to enhance patient safety. Pharmacodynamics is the study of the molecular, biochemical, and physiological effects of drugs on cellular systems and site of action. Pharmacokinetics focuses on how the body affects the drug, in ADME terms. Today, Clinical Pharmacology techniques and pharmacologists use different techniques to explain and manipulate the pharmacological action for safer use health concerns.
This track provides information for drug product manufacturers, professionals, and consumers to report and informative B2B meetings can be planned.
Track 3: Clinical Research and Statistics
Track 4: Pre-Clinical and Clinical Trials
Track 5: Clinical Trials on Various Disorders
Track 6: Case Reports in Clinical Trials
Track 7: Good Pharmacovigilance Practice
Track 8: Pharmacovigilance Significance & Scope
Track 9: Pharmacovigilance and Risk Management
Track 10: Clinical Data Base Management
Data management plays an important role in the process of drug development and allowing early access to patients. A standardized approach is needed from Phase 1 to post-marketing trials.
Track 11: Analysis of Data quality and Management
Track 12: PV Consulting And Business opportunity
Track 13: Biopharmaceutics
Track 14: Regulatory Affairs
Regulatory Affairs is involved in all the stages of drug development and post-marketing activities. Clinical trials must adhere to regulatory guidelines.
Track 15: Pharmacy Practices and its Challenges
Track 16: Entrepreneurs Investment Meet
Oncology, Dermatology, Nephrology, Neurology, Gastroenterology, Hepatology, Cardiology, Infectious Disease
Conference organized by conference series LLC
Neurology is the study of injuries, disorders, diagnosis and treatment of thebrain, spine and nervoussystem including their coverings, blood vessels, and all effector tissues. There More than 600 known neurological disorders are there which affects our nervous system severely but still for most of the diseases treatment options are very limited and research is going on.
- JW Marriott Dubai